DOI: 10.1097/01.COT.0000294172.69829.ba

,  

Issn Print: 0276-2234

Publication Date: 2004/05/25


Print

HPV Vaccine: Early Data Promising

Heather Lindsey

    loading  Checking for direct PDF access through Ovid

Excerpt

Preliminary study results for HPV vaccination are very promising, noted Jacqueline Sherris, PhD, a reproductive health specialist at PATH, the Program for Appropriate Technology in Health.
However, preventing cervical cancer in the developing world with an HPV vaccine will not replace screening and treatment, she cautioned. “It will be very difficult to get 100% coverage [with an HPV vaccine].”
Modeling studies indicate that HPV vaccines can provide about 30% to 40% reduction of incidence of cervical cancer, said Sylvia C. Robles, MD, MSc, Unit Chief of Noncommunicable Diseases for the Pan American Health Organization, who predicted that preventing cervical cancer will involve HPV vaccination in addition to screening programs.
And as Micol Salvetto, MSc, a Nicaragua-based health consultant for the Central American Health Institute, noted, because a number of HPV types exist, vaccines are likely to be type specific, which would limit their impact and make some form of screening still necessary.

Related Topics

    loading  Loading Related Articles